• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Smith & Nephew Stock Gets A Fresh Robotics Cash Flow Test

    Simply Wall St·11/05/2026 06:48:14
    Listen to the news
    • Recent commentary on Smith & Nephew highlights the medical device group as undervalued, with its Orthopaedics segment and cash flow potential supported by recurring implant procedures and surgeon loyalty.
    • A key development is the growth of the CORI handheld robotics platform, where rising placements support a higher mix of recurring software, service and implant revenue per site.
    • This article now examines how Smith & Nephew's investment narrative is affected by its growing reliance on CORI robotics for recurring cash flows.

    Scan beyond Smith & Nephew and compare its robotics and cash flow profile with a curated group of medical and tech enablers in our 9 healthcare AI stocks.

    Smith & Nephew Investment Narrative Recap

    To own Smith & Nephew, you need to be comfortable with a story built around Orthopaedics and recurring cash flows from CORI supported procedures. The key near term swing factor is still execution on the orthopaedics reset, especially getting U.S. knees back on a steadier footing while keeping CORI utilization and surgeon adoption moving in the right direction.

    The biggest operational risk stays the same. Weakness in U.S. knees and reimbursement pressure in Advanced Wound Bioactives could offset progress in robotics and biologics and keep group growth patchy. The CORI focused news does not materially change that risk balance; it mostly reinforces that near term story.

    The clearest link to this robotics narrative is the push behind CORI handheld placements, which are reported to be growing at a double digit rate. That matters because each new site can support more software, service and implant revenue per procedure, so your view on Smith & Nephew probably hinges on how effectively management turns that installed base into repeat usage.

    On the flip side, higher CORI penetration raises the execution bar. Any slowdown in placements, weaker ambulatory surgery center uptake or reduced procedure mix could blunt this recurring revenue opportunity. When you weigh catalysts today, the CORI rollout, the 12 point cost program and Advanced Wound Bioactives reimbursement pressure now feel like tightly linked parts of the same operational test.

    Smith & Nephew's narrative projects US$7.4b revenue and US$975.4m earnings by 2029, based on analysts' assumption of 5.4% yearly revenue growth and an earnings increase of about US$340m from US$635.0m today.

    Discover why Smith & Nephew's fair value indicates a 6% potential upside to its current price that may not last much longer.

    LSE:SN. 1-Year Stock Price Chart
    LSE:SN. 1-Year Stock Price Chart

    Exploring Other Perspectives

    Fair value views on Smith & Nephew from the Simply Wall St Community cluster between about US$12.62 and US$17.76 per share across 2 separate estimates, so private investors are already spread across a wide band. Those opinions pre date the latest CORI and Orthopaedics updates. Revisit them, compare the risks and catalysts above, and test how your own thesis might differ.

    Explore another Smith & Nephew fair value estimate, including one that suggests as much as 49% upside from the current price!

    The Verdict Is Yours

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider your own analysis and judgment.

    Looking For More Investment Ideas Beyond Smith & Nephew?

    Once you have formed a view on Smith & Nephew, it can help to widen the lens and line it up against other opportunities that match your style, risk tolerance and time horizon. The Simply Wall St screener lets you jump straight into focused shortlists rather than wading through thousands of tickers from scratch.